Management of Refractory Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia with Bevacizumab
نویسندگان
چکیده
منابع مشابه
Hereditary Hemorrhagic Telangiectasia Management.
Hereditary hemorrhagic telangiectasia (HHT) is an inherited disorder that can lead to frequent and severe sequelae. Although the condition has no cure, many of its physical symptoms can be managed to improve the quality of life and lower the risk of life-threatening complications. This article discusses HHT presentation, genetic screening, diagnosis, and management. The management of HHT can in...
متن کاملHereditary hemorrhagic telangiectasia treated with low dose intravenous bevacizumab
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder that leads to mucocutaneous telangiectasias, epistaxis, and gastrointestinal bleeding. Depending on the severity and manifestation of the disease, various therapeutic modalities have been used, from local bleeding control to surgery or concomitant drug therapy. Several articles under review have presented guidelines f...
متن کاملBevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia.
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease characterized by mucocutaneous and visceral telangiectasia. Hepatic involvement with vascular malformations may lead to portal hypertension, biliary ischemia, and high-output cardiac failure. Liver transplantation is indicated for life-threatening disease but carries significant risk from surgery and chronic immunosupp...
متن کاملIs bevacizumab effective for reducing epistaxis in hereditary hemorrhagic telangiectasia?
BACKGROUND Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, often manifests with epistaxis. The disease spectrum is wide; some patients have small, irritating bleeds, whereas other patients require monthly blood transfusions. There are many medical and surgical interventions for epistaxis in HHT, but none have been established as a gold-standard treatment. ...
متن کاملBlessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia.
Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder characterized by uncontrolled multisystem angiogenesis with epistaxis, gastrointestinal bleeding, iron-deficiency anemia, and arteriovenous malformations, and is often associated with increased levels of vascular endothelial growth factor (VEGF). Bevacizumab, a VEGF inhibitor, reduces epistaxis, telangiectasias, and iron-deficien...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Case Reports in Gastrointestinal Medicine
سال: 2021
ISSN: 2090-6536,2090-6528
DOI: 10.1155/2021/2242178